4.7 Review

Neurotransmitter and Intestinal Interactions: Focus on the Microbiota-Gut-Brain Axis in Irritable Bowel Syndrome

Journal

FRONTIERS IN ENDOCRINOLOGY
Volume 13, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2022.817100

Keywords

neurotransmitters; irritable bowel syndrome; microbiota-gut-brain axis; 5-HT; dopamine; GABA; histamine

Funding

  1. Army Medical University Project [2017XYY06]
  2. Chongqing Science and Health Joint Project [2019ZDXM026]
  3. Army Medical Center Military Medical Frontier Innovation Capability Program [2019CXJSB008]

Ask authors/readers for more resources

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder with unknown causes, and disruption in the gut-brain axis is believed to be the cause. Recent studies have shown that neurotransmitters play an important role in IBS, affecting blood flow regulation, intestinal motility, immune system, and gut microbiota. These studies have shed light on the mechanisms of neurotransmitters in the pathogenesis of IBS and provided new therapeutic strategies targeting the nervous system or microbiota.
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder of unknown etiology. IBS is caused by a disruption in the gut-brain axis. Given the importance of the gut microbiota in maintaining local and systemic homeostasis of immunity, endocrine, and other physiological processes, the microbiota-gut-brain axis has been proposed as a key regulator in IBS. Neurotransmitters have been shown to affect blood flow regulation, intestinal motility, nutrient absorption, the gastrointestinal immune system, and the microbiota in recent studies. It has the potential role to play a function in the pathophysiology of the gastrointestinal and neurological systems. Transmitters and their receptors, including 5-hydroxytryptamine, dopamine, gamma-aminobutyric acid, and histamine, play an important role in IBS, especially in visceral sensitivity and gastrointestinal motility. Studies in this field have shed light on revealing the mechanism by which neurotransmitters act in the pathogenesis of IBS and discovering new therapeutic strategies based on traditional pharmacological approaches that target the nervous system or novel therapies that target the microbiota.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available